These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 9704165)

  • 1. The phosphodiesterase i.v. inhibitor rolipram in vitro reduces the numbers of MBP-reactive IFN-gamma and TNF-alpha mRNA expressing blood mononuclear cells in patients with multiple sclerosis.
    Navikas V; Matusevicius D; Söderström M; Pirskanen R; Fredrikson S; Link H
    Clin Neuropharmacol; 1998; 21(4):236-44. PubMed ID: 9704165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon-gamma, interleukin-4 and transforming growth factor-beta mRNA expression in multiple sclerosis and myasthenia gravis.
    Link J
    Acta Neurol Scand Suppl; 1994; 158():1-58. PubMed ID: 7732782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased transforming growth factor-beta, interleukin-4, and interferon-gamma in multiple sclerosis.
    Link J; Söderström M; Olsson T; Höjeberg B; Ljungdahl A; Link H
    Ann Neurol; 1994 Sep; 36(3):379-86. PubMed ID: 8080246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Organ-specific autoantigens induce transforming growth factor-beta mRNA expression in mononuclear cells in multiple sclerosis and myasthenia gravis.
    Link J; Fredrikson S; Söderström M; Olsson T; Höjeberg B; Ljungdahl A; Link H
    Ann Neurol; 1994 Feb; 35(2):197-203. PubMed ID: 7509140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of interferon-gamma, interleukin-4, and transforming growth factor-beta in rats orally tolerized against experimental autoimmune myasthenia gravis.
    Wang ZY; Link H; Ljungdahl A; Höjeberg B; Link J; He B; Qiao J; Melms A; Olsson T
    Cell Immunol; 1994 Sep; 157(2):353-68. PubMed ID: 7520837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transforming growth factor-beta 1 suppresses autoantigen-induced expression of pro-inflammatory cytokines but not of interleukin-10 in multiple sclerosis and myasthenia gravis.
    Link J; He B; Navikas V; Palasik W; Fredrikson S; Söderström M; Link H
    J Neuroimmunol; 1995 Apr; 58(1):21-35. PubMed ID: 7537278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic immunomodulatory effects of interferon-beta1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing-remitting multiple sclerosis.
    Weber F; Polak T; Günther A; Kubuschok B; Janovskaja J; Bitsch A; Poser S; Rieckmann P
    Ann Neurol; 1998 Jul; 44(1):27-34. PubMed ID: 9667590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-alpha generation from human peripheral blood monocytes.
    Seldon PM; Barnes PJ; Giembycz MA
    Cell Biochem Biophys; 1998; 29(1-2):179-201. PubMed ID: 9631245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [IL-2, IFN-gamma, and TNF-alpha mRNA expression in peripheral blood mononuclear cells in patients with multiple sclerosis].
    Lin J; Li L; Gao Y; Min B; Xu X
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1997 Feb; 19(1):24-8. PubMed ID: 10453548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase.
    Seldon PM; Barnes PJ; Meja K; Giembycz MA
    Mol Pharmacol; 1995 Oct; 48(4):747-57. PubMed ID: 7476903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphodiesterase 4 inhibitors prevent cytokine secretion by T lymphocytes by inhibiting nuclear factor-kappaB and nuclear factor of activated T cells activation.
    Jimenez JL; Punzón C; Navarro J; Muñoz-Fernández MA; Fresno M
    J Pharmacol Exp Ther; 2001 Nov; 299(2):753-9. PubMed ID: 11602691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors.
    Verghese MW; McConnell RT; Strickland AB; Gooding RC; Stimpson SA; Yarnall DP; Taylor JD; Furdon PJ
    J Pharmacol Exp Ther; 1995 Mar; 272(3):1313-20. PubMed ID: 7891349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic immune response in whiplash injury and ankle sprain: elevated IL-6 and IL-10.
    Kivioja J; Ozenci V; Rinaldi L; Kouwenhoven M; Lindgren U; Link H
    Clin Immunol; 2001 Oct; 101(1):106-12. PubMed ID: 11580233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-inflammatory potential of the selective phosphodiesterase 4 inhibitor N-(3,5-dichloro-pyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), in human cell preparations.
    Draheim R; Egerland U; Rundfeldt C
    J Pharmacol Exp Ther; 2004 Feb; 308(2):555-63. PubMed ID: 14610230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of rolipram, a selective inhibitor of type 4 phosphodiesterase, on lipopolysaccharide-induced uveitis in rats.
    Chi ZL; Hayasaka S; Zhang XY; Hayasaka Y; Cui HS
    Invest Ophthalmol Vis Sci; 2004 Aug; 45(8):2497-502. PubMed ID: 15277469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-12 elispot assays to detect and enumerate IL-12 secreting cells.
    Ozenci V; Kouwenhoven M; Press R; Link H; Huang YM
    Cytokine; 2000 Aug; 12(8):1218-24. PubMed ID: 10930299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokine regulation of tumor necrosis factor-alpha and -beta (lymphotoxin)-messenger RNA expression in human peripheral blood mononuclear cells.
    Kasid A; Director EP; Stovroff MC; Lotze MT; Rosenberg SA
    Cancer Res; 1990 Aug; 50(16):5072-6. PubMed ID: 1696166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of TNF-alpha expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by rolipram.
    Ross SE; Williams RO; Mason LJ; Mauri C; Marinova-Mutafchieva L; Malfait AM; Maini RN; Feldmann M
    J Immunol; 1997 Dec; 159(12):6253-9. PubMed ID: 9550429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of TNF-alpha production in human mononuclear cells by an adenosine kinase inhibitor.
    Eigler A; Matschke V; Hartmann G; Erhardt S; Boyle D; Firestein GS; Endres S
    J Leukoc Biol; 2000 Jul; 68(1):97-103. PubMed ID: 10914495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term treatment of relapsing remitting multiple sclerosis patients with interferon (IFN)-beta1B transiently increases the blood levels of interleukin (IL)-6, IL-10 and IFN-gamma without significantly modifying those of IL-1beta, IL-2, IL-4 and tumour necrosis factor-alpha.
    Nicoletti F; Di Marco R; Patti F; Zaccone P; L'Episcopo MR; Reggio E; Xiang M; Nicoletti A; Reggio A
    Cytokine; 2000 Jun; 12(6):682-7. PubMed ID: 10843745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.